Want to see MEDP full AI Analyst Report?
MEDP Stock Chart & Stats
$614.06
-$4.97(-0.83%)
At close: 4:00 PM EDT
$614.06
-$4.97(-0.83%)
Day’s Range― - ―
52-Week Range$373.00 - $677.90
Previous CloseN/A
Volume71.74K
Average Volume (3M)290.36K
Market Cap
$16.56B
Enterprise Value$14.76K
Total Cash (Recent Filing)$502.69M
Total Debt (Recent Filing)$120.10M
Price to Earnings (P/E)34.0
Beta1.01
Next Earnings
Oct 26, 2026EPS Estimate
4.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)17.39
Shares Outstanding27,911,655
10 Day Avg. Volume217,231
30 Day Avg. Volume290,363
Financial Highlights & Ratios
PEG Ratio1.82
Price to Book (P/B)35.29
Price to Sales (P/S)6.40
P/FCF Ratio23.76
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$580.20Price Target Upside-5.51% Downside
Rating ConsensusHold
Number of Analyst Covering11
EPS Forecast (FY)17.6
Revenue Forecast (FY)$2.85B
Bulls Say, Bears Say
Bulls Say
Strong Profitability And Cash GenerationHigh margins and free cash flow approximately matching net income indicate efficient delivery and strong earnings quality. This supports reinvestment, resilience through trial-cycle variability, and financial flexibility without relying heavily on external capital.
Backlog And Bookings Support Future GrowthRecord net bookings and a sizable backlog provide multi-period revenue visibility for a service business. The expected conversion of about $1.96B over the next 12 months supports utilization, staffing plans, and continued scale in clinical research services.
Constructive Operating OutlookManagement's updated outlook points to sustained double-digit expansion in revenue and EBITDA, suggesting demand, execution, and operating leverage remain favorable. Improving RFP activity, win rates, and moderated cancellations add support to the medium-term trajectory.
Bears Say
Cancellation Volatility Threatens Revenue VisibilityClinical programs can be stopped or delayed by funding, enrollment, or sponsor decisions, reducing expected awards and revenue conversion. Although cancellations moderated in Q2, continued volatility could impair backlog quality, staffing efficiency, and forecasting reliability.
Customer Concentration Increases Execution RiskDependence on a limited group of sponsors makes results more sensitive to changes in major programs, budgets, or relationships. Loss, delay, or reprioritization at a large customer could materially affect revenue, utilization, and operating margins.
Growth Has Decelerated And Costs Remain PressuredThe sharp slowdown from prior growth rates indicates a more mature or competitive phase, while elevated direct service costs can constrain incremental margins. High-single-digit headcount growth may add further expense before demand fully converts.
Medpace Holdings News
MEDP FAQ
What was Medpace Holdings’s price range in the past 12 months?
Medpace Holdings lowest stock price was $373.00 and its highest was $677.90 in the past 12 months.
What is Medpace Holdings’s market cap?
Medpace Holdings’s market cap is $16.56B.
When is Medpace Holdings’s upcoming earnings report date?
Medpace Holdings’s upcoming earnings report date is Oct 26, 2026 which is in 51 days.
How were Medpace Holdings’s earnings last quarter?
Medpace Holdings released its earnings results on Jul 22, 2026. The company reported $4.25 earnings per share for the quarter, beating the consensus estimate of $3.978 by $0.272.
Is Medpace Holdings overvalued?
According to Wall Street analysts Medpace Holdings’s price is currently Overvalued.
Does Medpace Holdings pay dividends?
Medpace Holdings does not currently pay dividends.
What is Medpace Holdings’s EPS estimate?
Medpace Holdings’s EPS estimate is 4.41.
How many shares outstanding does Medpace Holdings have?
Medpace Holdings has 27,911,655 shares outstanding.
What happened to Medpace Holdings’s price movement after its last earnings report?
Medpace Holdings reported an EPS of $4.25 in its last earnings report, beating expectations of $3.978. Following the earnings report the stock price went up 14.713%.
Which hedge fund is a major shareholder of Medpace Holdings?
Currently, no hedge funds are holding shares in MEDP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Medpace Holdings Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$580.20 (-5.51% Downside)
$580.20 (-5.51% Downside)
Blogger Sentiment
Bullish
MEDP Sentiment 75%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 89.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $85.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 0.1%
Last 30 Days ▲ 0.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
23.30%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
30.89%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Medpace Holdings
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
MEDP Company Deck
MEDP Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed solid financial and operational momentum: double‑digit revenue and EBITDA growth, sizable net new awards and backlog growth, strong cash generation, share repurchases, and constructive guidance for 2026. Management noted improving RFP and funding dynamics and moderation of cancellations in Q2. Key risks discussed include prior cancellation volatility, an elevated backlog conversion rate versus historical norms (driven by gating policies and portfolio composition), higher reimbursable costs in H1, and customer concentration. Overall, the positive financial results, record net bookings, and upward guidance outweigh the operational risks and uncertainties discussed.View all MEDP earnings summariesMEDP Revenue Breakdown
98.00% U.S.
2.00% Other
MEDP Stock 12 Month Forecast
Average Price Target
$580.20
▼(-5.51% Downside)
Technical Analysis
Ownership Overview
19.46% Insiders
21.84% Mutual Funds
22.28% Other Institutional Investors
13.35% Public Companies and
Individual Investors